Here, the authors present a unique presentation of an adolescent girl with a history of bulimia nervosa with multiple chronic episodes of voluntary purging, which were immediately followed by cannabis-induced hyperemesis.
Psychostimulant cessation can be associated with withdrawal symptoms. This study examined if dependence developed during lisdexamfetamine treatment for binge-eating disorder, as evidenced by presence of withdrawal symptoms after stopping treatment.
Dr Mota and colleagues reply to the letter "Posttraumatic Stress Disorder and Binge-Eating Disorder: Further Context and Additional Findings From a Nationally Representative Sample of Adults in the United States" by Grilo and Udo.
In this letter to the editor, Drs Grilo and Udo discuss a recent study that examined links between trauma, PTSD, and binge-eating symptoms; their perspective is set in the context of their own NESARC-based research on the topic.
Binge-eating disorder may be underdiagnosed due to a lack of awareness and inadequate physician-patient communication. This report describes physician knowledge of and attitudes about binge-eating disorder and the value and ease-of-use of the 7-Item Binge Eating Disorder Screener in clinical practice.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”